Incyte and Syndaxs Niktimvo (also known as the combination of the targeted therapy niktimab and the chemotherapy drug lenalidomide) has received FDA approval for the treatment of specific types of cancer. Niktimvo represents a novel treatment approach, combining a targeted agent with a well-established chemotherapy agent to improve patient outcomes in certain cancer types.